

Please try another search
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Name | Age | Since | Title |
---|---|---|---|
Patrick John Flynn | 72 | 2021 | Independent Director |
Daniel E. Troy | 60 | 2021 | Independent Director |
Jonathan C. Javitt | 65 | 2021 | Co-Founder, Chief Scientist & Director |
Sherry Anne Glied | 59 | 2021 | Independent Director |
Aaron Gorovitz | 63 | 2021 | Independent Director |
Herbert Raymond McMaster | 58 | 2021 | Independent Director |
Daniel C. Javitt | - | 2017 | Co-Founder & Chairman of Scientific Advisory Board |
Chaim Hurvitz | 61 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review